Emergent Biosolutions (EBS) revenue and earnings history
Emergent Biosolutions reported revenue of $743M for fiscal 2025 (year ended Dec 31, 2025), −28.8% on the year before, and net income of $52.6M.
Over 16 years, from fiscal 2009 to fiscal 2025, revenue grew at a compound rate of +7.5% a year.
Revenue and net income, 17 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $743M−28.8% | $100M | $52.6M | $171M | $13.8M | $157M | $16.2M | $24.9M | — | $205M | $590M | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Emergent Biosolutions (EBS) on OQRO.
Common questions
What was Emergent Biosolutions's revenue in fiscal 2025?
$743M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 27, 2026. That is −28.8% on fiscal 2024 ($1.04B).
How fast has Emergent Biosolutions's revenue grown?
From $235M in fiscal 2009 to $743M in fiscal 2025: a compound annual growth rate of +7.5% over 16 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Emergent Biosolutions tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
